Replimune Group Inc. releases IGNYTE trial data on RP1 plus nivolumab in anti-PD-1-failed melanoma
Replimune Group Inc. has released updated clinical data from the IGNYTE trial, which evaluates the combination of RP1 and nivolumab in patients with melanoma who have failed anti-PD-1 therapy. The document highlights mechanisms of resistance to immune checkpoint blockade and insights into the tumor microenvironment, suggesting potential for renewed sensitivity to anti-PD-1 treatment. The full document is available via a provided link.
Replimune Group Inc. published a document detailing biomarker and updated clinical data from the IGNYTE trial evaluating RP1 plus nivolumab in anti-PD-1-failed melanoma. The document discusses mechanisms of resistance to immune checkpoint blockade and presents findings on the tumor microenvironment and potential for restored sensitivity to anti-PD-1 therapy. The full document can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
